|
Urologix, Inc. - Sales Analysis Snapshot
Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Urologix, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.
Urologix, Inc.. The Company's principal activity is to develop, manufacture and market non-surgical, catheter-based therapies for the treatment of benign prostatic hyperplasia. The Group market its control units under the CoolWave(R) and Targis(R) names and its procedure kits under the CTC AdvanceTM, CTCTM, Targis, and ProstaprobeTM names. It uses a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia disease. The Cooled ThermoTherapy can be performed without anesthesia or intravenous sedation and it can be performed in a physician's office or an outpatient clinic. The therapy provides a safe solution that is superior to medication without the complications and side effects inherent in surgical procedures. It manufacture the Targis control unit, CoolWave control unit, and single-use treatment catheters. The Company operates in the United States, Europe, Canada, Asia and other countries.
Not the Report you are looking for? Click here for more browsing options.
Layout and Content of a Typical Report
|
